First Targeted Therapy for Exon 20 Insertions in NSCLC Wins FDA Accelerated Approval

First Targeted Therapy for Exon 20 Insertions in NSCLC Wins FDA Accelerated Approval

(MedPage Today) -- The FDA granted accelerated approval to the tyrosine kinase inhibitor sunvozertinib (Zegfrovy) for advanced non-small cell lung cancer (NSCLC) associated with EGFR exon 20 insertions, the agency said. The approval stipulates...

Sunvozertinib Approved by FDA as Oral Treatment of NSCLC With EGFR Exon 20 Insertion Mutations

Sunvozertinib becomes the first and only targeted approval treatment for patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

FDA Approves Sunvozertinib in Non–Small Cell Lung Cancer

The treatment marks the only targeted oral treatment in patients with non–small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations.